Innocoll Inc

ASHBURN, Va., December 20, 2005 /PRNewswire/ — Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, has filed a US 510k application for CollaGUARD™, an advanced wound care product based on Innocoll’s proprietary CollaRx™ membrane technology. CollaGUARD has already received CE-mark approval for marketing in Europe and will be ready for launch in European markets in 2006. It is indicated for the management of superficial and deep wounds, including coverage of skin ulcers and temporary dermatoplasty in the case of lesion and burns.

INNOCOLL ANNOUNCES NEW DISTRIBUTION AGREEMENTS FOR CollaRx GENTAMICIN SURGICAL IMPLANT ASHBURN, Va., December 12, 2005 /PRNewswire/ -– Innocoll, Inc. announced it's sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed distribution agreements for it's CollaRx GENTAMICIN SURGICAL IMPLANT in five additional territories; Turkey, Greece, Romania, Bulgaria, and Nigeria.

ASHBURN, Va., September 8, 2005 /PRNewswire/ -–Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies, has entered into an agreement with Medexis SA, part of the Gerolymatos Group of Companies, for the development of a wound healing product based on Innocoll’s CollaRx™ membrane technology.

ASHBURN, Va., July 28, 2005 /PRNewswire/ – Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Technologies, has entered into a development and distribution agreement with Surgical-IOC for the development of an adhesion barrier product based on Innocoll’s CollaRx™ technology. Innocoll has granted Surgical-IOC exclusive worldwide rights to market and distribute potential products derived from the CollaRx technology for the specific indication of the prevention of surgical adhesions, with the exception of North America, Japan and Australasia.

ASHBURN, Va., July 14, 2005 /PRNewswire/ – Innocoll, Inc. announced it has recently signed an agreement with Essex Chemie AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP), under which it will obtain marketing rights to GENTAMICIN SURGICAL IMPLANT.

ASTON, Pa., June 17, 2005 /PRNewswire/ – Innocoll, Inc., announced it has recently entered into a collaboration with the University of Iowa to evaluate the utility of Innocoll’s LiquiColl® technology as a gene delivery vehicle for the treatment of certain cancers.

ASTON, Pa., March 9, 2005 / PRNewswire / – Innocoll, Inc. announced that its wholly-owned subsidiary, Syntacoll AG, has been granted two important patents. US Patent No. 6,855,860 entitled “Composite Dressings for Treatment of Wounds” was issued by the United States Patent and Trademark Office and patent No. 1263485 entitled “Multilayer Collagen Matrix for Tissue Reconstruction” by the European Patent Office.